ATRA use in Acute Promyelocytic Leukemia
Kirkuk Journal of Medical Sciences,
AbstractRetrospective study, carried between January 2001, and August 2006, Ninety four children (c 15 years of ages) were diagnosed as AML by bone marrow examination (aspirate and sometimes biopsy), twenty two of these children diagnosed as APL, fourteen were treated by chemotherapy and eight of these children treated by ATRA and specific protocol.
The information of this study was obtained from files of patients in hematology and oncology unit in central teaching hospital from children regarding age, sex, resistance, type of AML, complete blood count at diagnosis, response to treatment complication during treatment.
The treatment plan of these eight patient in induction was ATRA (25 mg/m2/day) administrated orally in two equally divided doses associated with daunorubicin (25 mg/m2/day) for two consecutive day only for those with WBCc >10 ×109/L at day one, WBCc > 5×10 9/L at day fifteen at which bone marrow aspiration done this cycle continued for thirty day. In consolidation cycle which includes cycles of daunorubicin stander dose cytorabine by subcutaneous injection with ATRA orally in two divided doses. Oral 6- mercaptopurine and methotrexate combined with ATRA every 3 month was administrated to all patient who obtained complete remission (CR) (
- Article View: 9
- PDF Download: 0